Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn

By C. Chambers, S. Hernández-Díaz, L. V. van Marter, M. Werler, C. Louik, K. Jones, A. Mitchell. New England Journal of Medicine, 2006

842 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/39189b500f0837f572ff03d555e327ca134b9962

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Calabrese
2. Bryan L. Roth
3. Miles Berger
4. J. A. Gray
5. Eduard Vieta
6. F. Kapczinski
7. A. Young

Citations in the corpus

• Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. (2009, background): “In utero exposure to SSRIs can also have an impact on the neonate, with reports of neonatal abstinence syndrome (117) and persistent pulmonary hypertension of the newborn (118).”
• Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders (2014, neutral): “tension in the antenatally exposed infant have not been consistent [1124-1127].”
• The Expanded Biology of Serotonin (2009, positive): “However, exposure to SSRIs during pregnancy may increase the newborn’s risk of developing persistent pulmonary hypertension (75).”